Benitec Biopharma Inc. Cash Flow Statement
BNTC|2 years of annual SEC 10-K data (FY2020-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Benitec Biopharma Inc. used $8M in operating cash flow and negative free cash flow of $8M in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.32 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 |
|---|---|---|
| Net Income | -$8.3M | $2.6M |
| Depreciation & Amortization | $190.0K | $158.0K |
| Operating Cash Flow | -$7.5M | $4.8M |
| Capital Expenditures | $95.0K | $404.0K |
| Free Cash Flow | -$7.6M | $4.4M |
| FCF Margin | -7480.4% | 35.9% |